MANAGE-VT Registry - MANAGEment of Ventricular Tachycardia Outcomes Registry

Ventricular Tachycardia Clinical Trial

— MANAGE-VT  

Official title:

MANAGEment of Ventricular Tachycardia Outcomes Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06455488
• Other study ID #: 2020-CSF-00300
• Status: Recruiting
• Start date: July 20, 2020
• Est. completion date: July 20, 2030

Study information

• Verified date: June 2024
• Source: CorVita Science Foundation
• Contact: Martin C Burke, DO
• Phone: 7735208322
• Email: mburke[@]corvitahealth.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Data collection registry for patients with ventricular tachycardia to help physicians give better care for patients clinically and procedurally.

Description:

After consent from a patient the research team will input patients data from many different categories. There is a link to the PDF for the consent form, a patients anticoagulant medications will be assessed, their ventricular tachycardia (VT) history will be inputted, and their date of birth and zip code will inputted. The research team will then input any EKG's, echocardiograms, VT ablations, ICD's, S-ICD's, lab results, and comorbidities.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: July 20, 2030
• Est. primary completion date: July 20, 2030
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be at least 18 years old
• Must not be Exclusion Criteria: -

Related Conditions & MeSH terms

• Tachycardia
• Tachycardia, Ventricular
• Ventricular Tachycardia

Intervention

Procedure:
• Ventricular Tachycardia Ablation
This is a surgical ablation meant to reset patients irregular rhythm back to sinus.

Device:
• ICD Implant
A pacemaker or defibrillator implant to prevent SCD

Drug:
• Antiarrhythmic drug
Drug therapies

Diagnostic Test:
• EKG
Monitoring EKG testing done on registry patients
• Cardioversion
Monitoring cardioversions on registry patients
• Echocardiogram
Monitoring echocardiogram testing done on patients

Locations

Country	Name	City	State
United States	Corvita Science Foundation	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
CorVita Science Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence of Ventricular Tachycardia	The natural progression of v-tach will be assessed through medical record review	July 20, 2020 - Present
Primary	Number of Participants with Risk of Sudden Cardiac Death	All events of sudden cardiac death that arise from patients with ventricular tachycardia	July 20, 2020 - Present
Primary	Prevent Risk of Stroke	All strokes, transient ischemic and systemic thrombo-embolic events	July 20, 2020 - Present